<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Epileptol</journal-id><journal-id journal-id-type="iso-abbrev">Acta Epileptol</journal-id><journal-title-group><journal-title>Acta Epileptologica</journal-title></journal-title-group><issn pub-type="ppub">2096-9384</issn><issn pub-type="epub">2524-4434</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40405271</article-id><article-id pub-id-type="pmc">PMC12100784</article-id>
<article-id pub-id-type="publisher-id">223</article-id><article-id pub-id-type="doi">10.1186/s42494-025-00223-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Gui</surname><given-names>Jianxiong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Lingman</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Linxue</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xiaofang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Jiannan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jiang</surname><given-names>Li</given-names></name><address><email>dr_jiangcqmu@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02z1vqm45</institution-id><institution-id institution-id-type="GRID">grid.411472.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1764 1621</institution-id><institution>Children&#x02019;s Medical Center, </institution><institution>Peking University First Hospital, </institution></institution-wrap>Beijing, 100034 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05pz4ws32</institution-id><institution-id institution-id-type="GRID">grid.488412.3</institution-id><institution>Department of Neurology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, </institution><institution>Children&#x02019;s Hospital of Chongqing Medical University, </institution></institution-wrap>Chongqing, 400014 China </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>7</volume><elocation-id>31</elocation-id><history><date date-type="received"><day>10</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and&#x000a0;Drug&#x000a0;Administration Adverse Event Reporting System (FAERS) database.</p></sec><sec><title>Methods</title><p id="Par2">This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).</p></sec><sec><title>Results</title><p id="Par3">A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, <italic>n</italic>&#x02009;=&#x02009;116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, <italic>n</italic>&#x02009;=&#x02009;291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, <italic>n</italic>&#x02009;=&#x02009;70 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.</p></sec><sec><title>Conclusions</title><p id="Par4">This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s42494-025-00223-5.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antiseizure medications</kwd><kwd>Adverse events</kwd><kwd>Children</kwd><kwd>FAERS database</kwd><kwd>Psychiatric disorders</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2024M760146</award-id><principal-award-recipient><name><surname>Gui</surname><given-names>Jianxiong</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; West China Hospital 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par26">Epilepsy is a chronic neurological disorder characterized by a persistent predisposition to generate epileptic seizures and the resulting neurobiological, cognitive, psychological, and social implications of this condition [<xref ref-type="bibr" rid="CR1">1</xref>]. Epilepsy affects more than 70 million individuals worldwide, with nearly 80% residing in low- and middle-income nations [<xref ref-type="bibr" rid="CR2">2</xref>]. In most low-income countries, over 75% of individuals experiencing active epilepsy do not have access to adequate treatment [<xref ref-type="bibr" rid="CR3">3</xref>]. The global burden of epilepsy report estimates that annually, epilepsy accounts for 13 million disability-adjusted life years (DALYs), making it a significant global health concern [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par27">Epilepsy has a high incidence in early childhood [<xref ref-type="bibr" rid="CR5">5</xref>]. At the population level, the incidence exhibits a bimodal distribution, with the highest age-specific rate of 460 cases per 100,000 individuals observed among children under 5&#x000a0;years old and adults over 65 years old [<xref ref-type="bibr" rid="CR6">6</xref>]. The incomplete development of the brain may result in seizures having even more profound implications for children's cognitive and behavioral development [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par28">The cornerstone of treatment for most patients with epilepsy lies in the administration of antiseizure medications (ASMs). Approximately 70% of individuals who have recently been diagnosed with epilepsy can effectively manage their seizures with a single medication [<xref ref-type="bibr" rid="CR2">2</xref>]. Despite the wide range of available drugs globally, the selection of ASMs should consider the specific type of epilepsy and its corresponding syndrome, as well as the patient's age, gender, comorbidities, and potential drug interactions [<xref ref-type="bibr" rid="CR8">8</xref>]. Currently, ASMs are primarily categorized into three generations: the first generation, the second generation, and the third generation. The first-generation ASMs, such as phenytoin, carbamazepine, and valproic acid, have been extensively utilized in clinical practice over the past few decades; however, they exhibit significant side effects including cognitive dysfunction and behavioral issues [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. The second-generation ASMs like lamotrigine, topiramate, and levetiracetam have demonstrated improvements in terms of efficacy and safety; nevertheless, certain adverse effects persist such as skin rashes, weight fluctuations, and mood swings [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>,&#x000a0;<xref ref-type="bibr" rid="CR14">14</xref>]. The third-generation ASMs such as lacosamide, eslicarbazepine, and pregabalin have exhibited favorable outcomes in treating specific types of epilepsy; nonetheless, their long-term safety necessitates further investigation [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. According to a global survey conducted by the International League Against Epilepsy (ILAE) in 2022, it was found that most countries had widespread availability of at least one first-generation ASM, with carbamazepine being reported as the predominant choice globally. However, second- and third-generation ASMs were found to have limited utilization in low- and middle-income countries [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par29">Psychiatric symptoms commonly manifest in individuals with epilepsy, including but not limited to depression, anxiety, and aggression [<xref ref-type="bibr" rid="CR18">18</xref>]. Children with epilepsy could exhibit symptoms of attention deficit hyperactivity disorder (ADHD) and depressive symptoms [<xref ref-type="bibr" rid="CR19">19</xref>]. Several studies have investigated the shared genetic and neurobiological mechanisms underlying epilepsy and psychiatric disorders, yet a definitive conclusion has not been reached [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. An alternative perspective suggests that patients with epilepsy may experience psychiatric side effects after taking ASMs. Several ASMs, including phenobarbital, levetiracetam, gabapentin, felbamate, zonisamide, and topiramate have been associated with cognitive and behavioral adverse effects. Additionally, the use of vigabatrin has been linked to symptoms such as depression, irritability, hyperactivity, increased anxiety levels, psychosis, and insomnia [<xref ref-type="bibr" rid="CR19">19</xref>]. The implication is that it is crucial to be attentive and vigilant regarding potential psychiatric side effects following the administration of ASMs. The current studies on psychiatric adverse drug reactions (ADRs) caused by ASMs in children are limited, highlighting the need for increased attention and research in this specific area.</p><p id="Par30">The FDA Adverse Event Reporting System (FAERS) is one of the largest pharmacovigilance databases globally, encompassing comprehensive information on all adverse events (AEs) and medication error reports received by the FDA. Therefore, many studies have aimed to assess the potential adverse effects of post-marketing drugs in real-world use using the FAERS database [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par31">In this study, we utilized the documented AEs associated with ASMs in children to discern the AEs specifically linked to psychiatric disorders. These investigations may aid in identifying potential psychiatric adverse effects that are not delineated in drug labels, thereby enhancing the management of childhood epilepsy.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data source</title><p id="Par32">This study downloaded the American Standard Code for Information Interchange (ASCII) report files from the FAERS database for the period from the first quarter of 2004 to the first quarter of 2024. The data were imported into R software version 4.3.0 and processed using the"faersR"package.</p><p id="Par33">We included ASMs that have received FDA approval for the treatment of epilepsy or seizures, as listed in Table <xref rid="MOESM1" ref-type="media">S1</xref> [<xref ref-type="bibr" rid="CR24">24</xref>]. Reports mentioning brand names were reclassified under their corresponding generic names. Duplicate reports were eliminated from the analysis. Only reports suspecting ASMs as the primary drug associated with AEs were considered. Furthermore, this study exclusively focuses on patients below 18 years old. Considering that certain drugs were either not or infrequently used in pediatric patients (&#x0003c; 18 years old), we analyzed a total of 29 ASMs for AEs in the follow-up study.</p></sec><sec id="Sec4"><title>Statistical analysis</title><p id="Par34">In this study, the Medical Dictionary for Regulatory Activities (MedDRA) was employed to encode and analyze each preferred term (PT), which was subsequently mapped to the system organ classification (SOC) for further exploration [<xref ref-type="bibr" rid="CR25">25</xref>]. Firstly, the distribution of SOC features for the 29 ASMs underwent a descriptive analysis. Second, the reporting odds ratio (ROR) [<xref ref-type="bibr" rid="CR26">26</xref>], proportional reporting ratio (PRR) [<xref ref-type="bibr" rid="CR27">27</xref>], Bayesian Confidence Propagation Neural Network (BCPNN) [<xref ref-type="bibr" rid="CR28">28</xref>], and Multi-item Gamma Poisson Shrinker (MGPS) [<xref ref-type="bibr" rid="CR29">29</xref>] were employed to compute signal values. The utilization of multiple algorithms in combination enables cross-validation to mitigate false positives and enhance the precision of signal detection [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The algorithms and criteria are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The simultaneous fulfillment of four criteria was deemed to be indicative of significant signals.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of algorithms</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Algorithms</th><th align="left">Equation<sup>a</sup></th><th align="left">Criteria</th></tr></thead><tbody><tr><td align="left" rowspan="2">ROR</td><td align="left">ROR <inline-formula id="IEq1"><alternatives><tex-math id="d33e507">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$=\frac{(a/c)}{(b/d)}=\frac{ad}{bc}$$\end{document}</tex-math><mml:math id="d33e512"><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">ad</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">bc</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq1.gif"/></alternatives></inline-formula></td><td align="left" rowspan="2">a &#x02265;&#x02009;3, 95%CI (lower limit) &#x0003e;&#x02009;1</td></tr><tr><td align="left">95%CI <inline-formula id="IEq2"><alternatives><tex-math id="d33e549">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$={e}^{\text{ln}(ROR)\pm 1.96\sqrt{(\frac{1}{a}+\frac{1}{b}+\frac{1}{c}+\frac{1}{d})}}$$\end{document}</tex-math><mml:math id="d33e554"><mml:mrow><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mtext>ln</mml:mtext><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>R</mml:mi><mml:mi>O</mml:mi><mml:mi>R</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>&#x000b1;</mml:mo><mml:mn>1.96</mml:mn><mml:msqrt><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>a</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>d</mml:mi></mml:mfrac><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msqrt></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq2.gif"/></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="3">PRR</td><td align="left">PRR <inline-formula id="IEq3"><alternatives><tex-math id="d33e600">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$=\frac{a/(a+b)}{c/(c+d)}$$\end{document}</tex-math><mml:math id="d33e605"><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>a</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq3.gif"/></alternatives></inline-formula></td><td align="left" rowspan="3">a &#x02265;&#x02009;3, 95%CI (lower limit) &#x0003e;&#x02009;1, PRR &#x02265;&#x02009;2, <inline-formula id="IEq4"><alternatives><tex-math id="d33e635">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\chi }^{2}$$\end{document}</tex-math><mml:math id="d33e640"><mml:msup><mml:mrow><mml:mi>&#x003c7;</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq4.gif"/></alternatives></inline-formula> &#x02265; 4</td></tr><tr><td align="left">95%CI <inline-formula id="IEq5"><alternatives><tex-math id="d33e651">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$={e}^{\text{ln}(\text{PRR})\pm 1.96\sqrt{\frac{1}{a}-\frac{1}{a+b}+\frac{1}{c}-\frac{1}{c+d}}}$$\end{document}</tex-math><mml:math id="d33e656"><mml:mrow><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mtext>ln</mml:mtext><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>PRR</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>&#x000b1;</mml:mo><mml:mn>1.96</mml:mn><mml:msqrt><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>a</mml:mi></mml:mfrac><mml:mo>-</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mfrac><mml:mo>-</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:msqrt></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq5.gif"/></alternatives></inline-formula></td></tr><tr><td align="left"><inline-formula id="IEq6"><alternatives><tex-math id="d33e699">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\chi }^{2}=\frac{{\left(ad-bc\right)}^{2}(a+b+c+d)}{(a+b)(a+c)(c+d)(b+d)}$$\end{document}</tex-math><mml:math id="d33e704"><mml:mrow><mml:msup><mml:mrow><mml:mi>&#x003c7;</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mi>a</mml:mi><mml:mi>d</mml:mi><mml:mo>-</mml:mo><mml:mi>b</mml:mi><mml:mi>c</mml:mi></mml:mfenced></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq6.gif"/></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="6">BCPNN</td><td align="left">IC <inline-formula id="IEq7"><alternatives><tex-math id="d33e771">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$={\text{log}}_{2}\frac{p(x,y)}{p\left(x\right)p(y)}={\text{log}}_{2}\frac{a(a+b+c+d)}{(a+b)(a+c)}$$\end{document}</tex-math><mml:math id="d33e776"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mtext>log</mml:mtext><mml:mn>2</mml:mn></mml:msub><mml:mfrac><mml:mrow><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mfenced close=")" open="("><mml:mi>x</mml:mi></mml:mfenced><mml:mi>p</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>y</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mtext>log</mml:mtext><mml:mn>2</mml:mn></mml:msub><mml:mfrac><mml:mrow><mml:mi>a</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq7.gif"/></alternatives></inline-formula></td><td align="left" rowspan="6">IC025 &#x0003e;&#x02009;0</td></tr><tr><td align="left">E(IC)<inline-formula id="IEq8"><alternatives><tex-math id="d33e843">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$={\text{log}}_{2}\frac{(a+\gamma 11)(a+b+c+d+\alpha )(a+b+c+d+\beta )}{(a+b+c+d+\gamma )(a+b+\alpha 1)(a+c+\beta 1)}$$\end{document}</tex-math><mml:math id="d33e848"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mtext>log</mml:mtext><mml:mn>2</mml:mn></mml:msub><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:mn>11</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq8.gif"/></alternatives></inline-formula></td></tr><tr><td align="left">V(IC)<inline-formula id="IEq9"><alternatives><tex-math id="d33e933">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$=\frac{1}{{(\text{ln}2)}^{2}}\left\{\left[\frac{\left(a+b+c+d\right)-a+\gamma -\gamma 11}{(a+\gamma 11)(1+a+b+c+d+\gamma )}\right]+\left[\frac{\left(a+b+c+d\right)-\left(a+b\right)+\alpha -\alpha 1}{(a+b+\alpha 1)(1+a+b+c+d+\alpha )}\right]+\left[\frac{\left(a+b+c+d\right)-\left(a+c\right)+\beta -\beta 1}{(a+c+\beta 1)(1+a+b+c+d+\beta )}\right]\right\}$$\end{document}</tex-math><mml:math id="d33e938"><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>ln</mml:mtext><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mfrac><mml:mfenced close="}" open="{"><mml:mfenced close="]" open="["><mml:mfrac><mml:mrow><mml:mfenced close=")" open="("><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mfenced><mml:mo>-</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:mo>-</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:mn>11</mml:mn></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:mn>11</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced close="]" open="["><mml:mfrac><mml:mrow><mml:mfenced close=")" open="("><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mfenced><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi></mml:mfenced><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo>-</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced close="]" open="["><mml:mfrac><mml:mrow><mml:mfenced close=")" open="("><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi></mml:mfenced><mml:mo>-</mml:mo><mml:mfenced close=")" open="("><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi></mml:mfenced><mml:mo>+</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo>-</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mfenced></mml:mfenced></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq9.gif"/></alternatives></inline-formula></td></tr><tr><td align="left"><inline-formula id="IEq10"><alternatives><tex-math id="d33e1098">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\gamma =\gamma 11\frac{(a+b+c+d+\alpha )(a+b+c+d+\beta )}{(a+b+\alpha 1)(a+c+\beta 1)}$$\end{document}</tex-math><mml:math id="d33e1103"><mml:mrow><mml:mi>&#x003b3;</mml:mi><mml:mo>=</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:mn>11</mml:mn><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq10.gif"/></alternatives></inline-formula></td></tr><tr><td align="left">IC025 <inline-formula id="IEq11"><alternatives><tex-math id="d33e1165">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$=$$\end{document}</tex-math><mml:math id="d33e1170"><mml:mo>=</mml:mo></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq11.gif"/></alternatives></inline-formula> E(IC)&#x02212;2 <inline-formula id="IEq12"><alternatives><tex-math id="d33e1174">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sqrt{V(IC)}$$\end{document}</tex-math><mml:math id="d33e1179"><mml:msqrt><mml:mrow><mml:mi>V</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msqrt></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq12.gif"/></alternatives></inline-formula></td></tr><tr><td align="left">p.s.<inline-formula id="IEq13"><alternatives><tex-math id="d33e1194">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\alpha 1=\beta 1=1; \alpha =\beta =2; \gamma 11=1$$\end{document}</tex-math><mml:math id="d33e1199"><mml:mrow><mml:mi>&#x003b1;</mml:mi><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x0037e;</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo>=</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>&#x0037e;</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:mn>11</mml:mn><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq13.gif"/></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="2">MGPS</td><td align="left">EBGM <inline-formula id="IEq14"><alternatives><tex-math id="d33e1228">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$= \frac{a(a+b+c+d)}{(a+c)(a+b)}$$\end{document}</tex-math><mml:math id="d33e1233"><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>a</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq14.gif"/></alternatives></inline-formula></td><td align="left" rowspan="2">EBGM05 &#x0003e;&#x02009;2</td></tr><tr><td align="left">95%CI <inline-formula id="IEq15"><alternatives><tex-math id="d33e1272">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$={e}^{\text{ln}(EBGM)\pm 1.96\sqrt{(\frac{1}{a}+\frac{1}{b}+\frac{1}{c}+\frac{1}{d})}}$$\end{document}</tex-math><mml:math id="d33e1277"><mml:mrow><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mtext>ln</mml:mtext><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>E</mml:mi><mml:mi>B</mml:mi><mml:mi>G</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>&#x000b1;</mml:mo><mml:mn>1.96</mml:mn><mml:msqrt><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>a</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>d</mml:mi></mml:mfrac><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msqrt></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="42494_2025_223_Article_IEq15.gif"/></alternatives></inline-formula></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>ROR, reporting odds ratio; a, number of reports containing both the suspect drug and the suspect adverse drug reaction; b, number of reports containing the suspect adverse drug reaction with other medications (except the drug of interest); c, number of reports containing the suspect drug with other adverse drug reactions (except the event of interest); d, number of reports containing other medications and other adverse drug reactions; CI, confidence interval; PRR, proportional reporting ratio; &#x003c7;<sup>2</sup>, chi-square; BCPNN, Bayesian confidence propagation neural network; IC, information component; IC025, the lower confidence interval of IC; MGPS, multi-item gamma Poisson shrinker; EBGM, empirical Bayesian geometric mean; EBGM05, the lower 95% one-sided CI of EBGM</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec5"><title>Results</title><p id="Par35">At the PT level, this study employed four algorithms to analyze ADRs and evaluated compliance with various screening criteria. A total of 2539 PTs were included, involving 25 SOCs (Table S2). We incorporated less involved SOCs. The distribution of SOCs involved in the AEs of 29 ASMs is illustrated in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Nervous system disorders, skin and subcutaneous tissue disorders, and psychiatric disorders are the three most common SOCs when using ASMs in children.<fig id="Fig1"><label>Fig. 1</label><caption><p>Distribution of AE signals from ASMs in children from the FAERS database, classified based on SOCs level</p></caption><graphic xlink:href="42494_2025_223_Fig1_HTML" id="MO1"/></fig></p><p id="Par36">There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships (Table S3). The top 30 drug-PT relationships are presented in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, ranked according to the ROR. The drug-PT relationships with the top 5 signal strengths were lorazepam-withdrawal catatonia (<italic>n</italic>&#x02009;= 5, ROR 736.63, PRR 735.15, IC 8.52, EBGM 368.08), levetiracetam-epileptic psychosis (<italic>n</italic>&#x02009;= 3, ROR 270.29, PRR 270.25, IC 6.09, EBGM 68.31), pregabalin-drug use disorder (<italic>n</italic>&#x02009;= 44, ROR 215.33, PRR 211.84, IC 7.33, EBGM 160.87), valproic acid-social (pragmatic) communication disorder (<italic>n</italic>&#x02009;= 4, ROR 169.62, PRR 169.57, IC 6.19, EBGM 73.24), and pregabalin-substance use disorder (<italic>n</italic>&#x02009;= 6, ROR 159.81, PRR 159.46, IC 7.01, EBGM 128.79).<table-wrap id="Tab2"><label>Table 2</label><caption><p>The top 30 signal strength of psychiatric disorder-related AEs of ASMs in children ranked by ROR at the PTs level in the FAERS database</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">ASM</th><th align="left">PTs</th><th align="left">Case Reports</th><th align="left">ROR (95% CI)</th></tr></thead><tbody><tr><td align="left">Lorazepam</td><td align="left">withdrawal catatonia</td><td align="left">5</td><td align="left">736.63 (213.12, 2546.10)</td></tr><tr><td align="left">Levetiracetam</td><td align="left">epileptic psychosis</td><td align="left">3</td><td align="left">270.29 (28.11, 2598.63)</td></tr><tr><td align="left">Pregabalin</td><td align="left">drug use disorder</td><td align="left">44</td><td align="left">215.33 (153.04, 302.96)</td></tr><tr><td align="left">Valproic acid</td><td align="left">social (pragmatic) communication disorder</td><td align="left">4</td><td align="left">169.62 (37.96, 757.95)</td></tr><tr><td align="left">Pregabalin</td><td align="left">substance use disorder</td><td align="left">6</td><td align="left">159.81 (65.51, 389.88)</td></tr><tr><td align="left">Levetiracetam</td><td align="left">automatism epileptic</td><td align="left">8</td><td align="left">120.16 (41.69, 346.34)</td></tr><tr><td align="left">Topiramate</td><td align="left">self-induced vomiting</td><td align="left">6</td><td align="left">107.56 (41.72, 277.30)</td></tr><tr><td align="left">Lorazepam</td><td align="left">alcohol abuse</td><td align="left">5</td><td align="left">96.92 (38.12, 246.45)</td></tr><tr><td align="left">Levetiracetam</td><td align="left">childhood psychosis</td><td align="left">3</td><td align="left">90.10 (18.18, 446.42)</td></tr><tr><td align="left">Gabapentin</td><td align="left">psychiatric decompensation</td><td align="left">3</td><td align="left">79.39 (23.82, 264.56)</td></tr><tr><td align="left">Clonazepam</td><td align="left">substance use disorder</td><td align="left">3</td><td align="left">67.69 (20.57, 222.79)</td></tr><tr><td align="left">Topiramate</td><td align="left">alice in wonderland syndrome</td><td align="left">6</td><td align="left">62.05 (25.53, 150.81)</td></tr><tr><td align="left">Lamotrigine</td><td align="left">poverty of speech</td><td align="left">8</td><td align="left">60.25 (24.23, 149.8)</td></tr><tr><td align="left">Lorazepam</td><td align="left">disorganised speech</td><td align="left">5</td><td align="left">57.55 (23.14, 143.11)</td></tr><tr><td align="left">Pregabalin</td><td align="left">drug abuse</td><td align="left">208</td><td align="left">56.71 (48.98, 65.66)</td></tr><tr><td align="left">Clonazepam</td><td align="left">drug use disorder</td><td align="left">14</td><td align="left">52.85 (30.6, 91.27)</td></tr><tr><td align="left">Valproic acid</td><td align="left">executive dysfunction</td><td align="left">3</td><td align="left">47.70 (12.65, 179.83)</td></tr><tr><td align="left">Gabapentin</td><td align="left">personality disorder</td><td align="left">10</td><td align="left">46.22 (24.28, 87.98)</td></tr><tr><td align="left">Lorazepam</td><td align="left">generalised anxiety disorder</td><td align="left">4</td><td align="left">43.96 (16.02, 120.64)</td></tr><tr><td align="left">Valproic acid</td><td align="left">impaired reasoning</td><td align="left">6</td><td align="left">38.17(15.33, 95.06)</td></tr><tr><td align="left">Carbamazepine</td><td align="left">poverty of speech</td><td align="left">3</td><td align="left">37.34 (10.88, 128.18)</td></tr><tr><td align="left">Valproic acid</td><td align="left">learning disorder</td><td align="left">51</td><td align="left">37.19 (27.22, 50.83)</td></tr><tr><td align="left">Valproic acid</td><td align="left">automatism</td><td align="left">5</td><td align="left">35.34 (13.12, 95.20)</td></tr><tr><td align="left">Lamotrigine</td><td align="left">asocial behavior</td><td align="left">9</td><td align="left">33.89 (15.60, 73.610)</td></tr><tr><td align="left">Clonazepam</td><td align="left">mutism</td><td align="left">6</td><td align="left">33.88 (14.89, 77.09)</td></tr><tr><td align="left">Diazepam</td><td align="left">fear of death</td><td align="left">3</td><td align="left">33.82 (10.62, 107.72)</td></tr><tr><td align="left">Lamotrigine</td><td align="left">factitious disorder</td><td align="left">3</td><td align="left">31.06 (8.24, 117.08)</td></tr><tr><td align="left">Perampanel</td><td align="left">homicidal ideation</td><td align="left">4</td><td align="left">30.88 (11.46, 83.24)</td></tr><tr><td align="left">Topiramate</td><td align="left">bradyphrenia</td><td align="left">18</td><td align="left">30.30 (18.60, 49.36)</td></tr><tr><td align="left">Lorazepam</td><td align="left">persecutory delusion</td><td align="left">3</td><td align="left">29.44 (9.28, 93.41)</td></tr></tbody></table></table-wrap></p><p id="Par37">Based on the Diagnostic and Statistical Manual of Mental Disorders-5 th Edition (DSM-5) and International Classification of Diseases-10 th Edition (ICD-10), 110 PTs related to psychiatric disorders were classified into 10 categories for facilitating analysis and comprehension, which encompassed behavioral and impulse control disorders, cognitive and learning disorders, language and speech disorders, autism spectrum disorder related symptoms, mood and emotional disorders, psychotic symptoms, sleep disorders, substance dependence and abuse, suicidal and self-injurious behavior, and other neuropsychiatric symptoms (Table S4-5).</p><p id="Par38">Psychotic symptoms (mainly in lorazepam and topiramate, <italic>n</italic>&#x02009;= 116 and <italic>n</italic>&#x02009;= 109), substance dependence and abuse (mainly in pregabalin and clonazepam, <italic>n</italic>&#x02009;= 291 and <italic>n</italic>&#x02009;= 110), and the other neuropsychiatric symptoms (mainly seen in levetiracetam and valproic acid, <italic>n</italic>&#x02009;= 70 and <italic>n</italic>&#x02009;= 62) were the common types of psychiatric disorder-related AEs of ASMs in children. Behavioral and impulse control disorders were reported more frequently in levetiracetam and perampanel (<italic>n</italic>&#x02009;= 103 and <italic>n</italic>&#x02009;= 74). Cognitive and learning disorders were mainly found in valproic acid and lamotrigine (<italic>n</italic>&#x02009;= 104 and 36). Vigabatrin reported more mood and emotional disorders (<italic>n</italic>&#x02009;= 103) and sleep disorders (<italic>n</italic>&#x02009;= 110). Autism spectrum disorder related symptoms are mainly seen in valproic acid, levetiracetam, and lamotrigine (<italic>n</italic>&#x02009;= 93, <italic>n</italic>&#x02009;= 54, and <italic>n</italic>&#x02009;= 41) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Distribution of psychiatric disorder-related AEs of ASMs in children from the FAERS database</p></caption><graphic xlink:href="42494_2025_223_Fig2_HTML" id="MO2"/></fig></p><p id="Par39">Surprisingly, nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children. The drug-PT relationship with the highest signal strength was perampanel-homicidal ideation (<italic>n</italic>&#x02009;= 4, ROR 30.88, PRR 30.75, IC 4.92, EBGM 30.19). The most frequent was clonazepam-suicide attempt (<italic>n</italic>&#x02009;= 53, ROR 6.30, PRR 6.21, IC 2.62, EBGM 6.16) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and Table S5).<fig id="Fig3"><label>Fig. 3</label><caption><p>The associations between ASMs and AEs of suicidal and self-injurious behavior, based on ROR</p></caption><graphic xlink:href="42494_2025_223_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec6"><title>Discussion</title><p id="Par40">Children diagnosed with epilepsy frequently exhibit comorbid neuropsychiatric developmental disorders, including cognitive impairments, behavioral dysfunctions, psychiatric manifestations (such as anxiety and depression), language deficits, and sleep disorders. These associations may be attributed to specific childhood-onset epilepsy syndromes characterized by severe epileptic seizures and concurrent neurodevelopmental disorders, such as Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS) [<xref ref-type="bibr" rid="CR32">32</xref>]. The frequent seizures may also contribute to the development of psychiatric disorders. The nocturnal seizures can intensify sleep disorders, exacerbating cognitive and behavioral impairments [<xref ref-type="bibr" rid="CR33">33</xref>]. Apart from disease mechanisms, ASMs are also linked to a range of behavioral and psychological AEs, including irritability, attack, mood disorders, depression, and anxiety [<xref ref-type="bibr" rid="CR32">32</xref>]. In this study, we analyzed psychiatric disorders related to AEs of ASMs in children using reports collected from the FAERS database, aiming to provide valuable insights for clinical decision-making.</p><p id="Par41">The FAERS database remains a fundamental component of post-marketing pharmacovigilance, widely used to monitor drug safety and facilitate timely identification of potential safety concerns. It has been extensively utilized for evaluating the real-world potential adverse effects of ASMs [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. We used four methods to mine potential AE signals to increase the stability of the results. In the case of the most commonly used ROR, a high ROR value typically indicated a robust association between the drug and a specific AE. This association was further substantiated when accompanied by a substantial number of case reports (such as pregabalin-drug use disorder, <italic>n</italic>&#x02009;= 44, ROR 215.33). High ROR values combined with a low number of case reports suggest a potential association, but additional data are required for confirmation (such as lorazepam-withdrawal catatonia, <italic>n</italic>&#x02009;= 5, ROR 736.63). A low ROR value coupled with a high number of cases has been reported, which may indicate that the AEs represent various common drug reactions; however, caution should still be exercised due to the reporting numbers (such as vigabatrin-irritability, <italic>n</italic>&#x02009;= 103, ROR 4.47). Therefore, the AE signals that meet the screening criteria should be considered significant in clinical practice.</p><p id="Par42">A study involving 4085 adult patients newly initiated with ASM for epilepsy revealed that 17.2% of the patients experienced psychiatric and behavioral adverse effects, which were deemed intolerable by 13.8% of them. The study revealed that patients taking levetiracetam and zonisamide were more susceptible to experiencing adverse psychiatric and behavioral reactions. Levetiracetam primarily exhibited symptoms of irritability, aggression, other behavioral issues, depressive mood, and anxiety. Zonisamide mainly manifested as depressive mood and psychosis [<xref ref-type="bibr" rid="CR35">35</xref>]. Our study also found that levetiracetam had the highest case reports related to behavioral and impulse control disorders, primarily encompassing behavior disorders, impulse-control disorders, and hostility. Zonisamide also included AEs associated with psychotic symptoms (hallucination, visual and confusional state). Levetiracetam, perampanel, brivaracetam, valproic acid, and clonazepam were found to be associated with psychobehavioral AEs, such as aggression and irritability [<xref ref-type="bibr" rid="CR32">32</xref>]. Previous studies have suggested that lamotrigine can improve aggressive behavior in epilepsy patients [<xref ref-type="bibr" rid="CR36">36</xref>]. On the other hand, it has also been found that lamotrigine may exacerbate aggression and violent behavior in some patients [<xref ref-type="bibr" rid="CR37">37</xref>]. In this study, lamotrigine was found to be associated with antisocial behavior and conduct disorders, which were less frequently observed in previous research.</p><p id="Par43">Valproic acid, lamotrigine, and topiramate reported the highest number of cognitive and learning disorder AEs in our study. Valproic acid was considered to be associated with an increased risk of autism spectrum disorder, but there were few studies on its effect on cognitive function [<xref ref-type="bibr" rid="CR32">32</xref>]. It is important to note that the observed association may also be influenced by prescribing bias. Valproic acid is commonly used in clinical practice for children with epilepsy and co-occurring autism spectrum&#x000a0;(ASD) disorder due to its mood-stabilizing properties, which may contribute to improvements in core ASD symptoms [<xref ref-type="bibr" rid="CR38">38</xref>]. Several studies have reported a partial improvement in cognitive function among patients following lamotrigine therapy [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. A study of 87 children treated with topiramate reported that the main reason for discontinuation was deemed to be unacceptable cognitive dulling (27, 31%) [<xref ref-type="bibr" rid="CR41">41</xref>]. The variations in cognitive and learning outcomes may be associated with the stage of disease progression and the demographic characteristics of the population.</p><p id="Par44">Pregabalin, lorazepam, clonazepam, diazepam, phenytoin, clobazam, and carbamazepine were reported with substance dependence and abuse. Pregabalin has been suggested to have a modulatory effect on GABA and glutamate systems, leaving room for drug dependence [<xref ref-type="bibr" rid="CR42">42</xref>]. In one study, the likelihood of remaining drug-free dependent for 5&#x000a0;years of treatment with clobazam and clonazepam was 99.4% and 98.5%, respectively, in patients with epilepsy [<xref ref-type="bibr" rid="CR43">43</xref>]. The prescription should still be monitored for signs of abuse, particularly in patients with a prior history of substance misuse.</p><p id="Par45">It is worth noting that vigabatrin reported irritability (<italic>n</italic>&#x02009;= 103, ROR 4.47) and insomnia (<italic>n</italic>&#x02009;= 99, ROR 3.83) of the AEs. In a study of 135 children treated with vigabatrin as adjunctive therapy, agitation and insomnia were reported in 8.8% of patients, while somnolence was observed in 6% [<xref ref-type="bibr" rid="CR44">44</xref>]. In addition, among the AEs regarding vigabatrin, death was reported (<italic>n</italic>&#x02009;= 447, ROR 14.11) (Table S2). Although this is not the primary focus of this research, it is worth conducting a follow-up study to further explore and provide cautionary insights.</p><p id="Par46">Perampanel, tiagabine, eslicarbazepine, lorazepam, clonazepam, gabapentin, lamotrigine, brivaracetam, and diazepam were associated with suicidal and self-injurious behavior. In a case&#x02013;control study, the utilization of ASMs was found to be associated with an elevated risk of suicide (mortality rate ratio, MRR =&#x02009;1.26, 95%CI =&#x02009;1.13&#x02013;1.40) [<xref ref-type="bibr" rid="CR45">45</xref>]. The results of a meta-analysis revealed no evidence suggesting that ASMs (including eslicarbazepine, perampanel, and brivaracetam) were associated with an increased risk of suicidal ideation or attempts [<xref ref-type="bibr" rid="CR46">46</xref>]. Despite the absence of convincing evidence linking ASMs to an elevated risk of suicidal and self-injurious behavior, it is still imperative to remain vigilant regarding these potential AEs.</p><p id="Par47">We also identified some rare AEs that deserve attention and vigilance. For example, lamotrigine-related Munchausen's syndrome (<italic>n</italic>&#x02009;= 4, ROR 15.00), a mental disorder in which one fantasizes about being sick to seek medical attention or be hospitalized; valproic acid-related automatism (<italic>n</italic>&#x02009;= 5, ROR 35.34), the unconscious or uncontrolled state in which certain movements or behaviors are performed. These AE signals played a crucial role in guiding the assessment of drug safety, risk management, and clinical decision-making.</p><p id="Par48">Caution is warranted when interpreting the associations between certain ASMs and psychiatric AEs, particularly for agents like lamotrigine and valproic acid, which are also recognized for their mood-stabilizing properties. Lamotrigine, beyond its broad-spectrum efficacy in seizure control, is approved by the FDA for the treatment of bipolar disorder and has shown promise in managing affective symptoms in pediatric epilepsy populations [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Valproic acid, similarly, is frequently prescribed in children with epilepsy and co-occurring ASD, owing to its dual role in seizure suppression and positive modulation of behavioral symptoms, which may contribute to improvements in core ASD features [<xref ref-type="bibr" rid="CR38">38</xref>]. Therefore, the observed associations&#x02014;such as lamotrigine with suicidality and valproic acid with ASD&#x02014;may not reflect true adverse drug effects but rather result from prescribing bias, wherein these medications are preferentially selected for patients with specific neuropsychiatric comorbidities. These considerations underscore the importance of interpreting such associations with care and highlight the need for future studies that integrate detailed clinical and diagnostic information to distinguish causal drug effects from treatment indications.</p><p id="Par49">ASMs exert their antiepileptic effects through multiple mechanisms and by targeting a range of molecular substrates, including the enhancement of GABAergic inhibition, suppression of glutamatergic excitation, direct modulation of synaptic release, and regulation of voltage-gated ion channel conductance [<xref ref-type="bibr" rid="CR49">49</xref>]. Notably, these biological targets are also critically involved in the regulation of mood and behavior [<xref ref-type="bibr" rid="CR50">50</xref>], which may partly explain why ASMs are associated with specific potential neuropsychiatric ADRAs. Studies have shown that some ASMs enhancing GABAergic transmission, such as phenobarbital, benzodiazepines, topiramate, and tiagabine, may induce GABAergic hyperactivity, disrupting mood regulation and leading to neuropsychiatric symptoms like depression, irritability, impulsive aggression, and hyperactivity [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. These effects are more common in children and individuals with a prior history of psychiatric disorders [<xref ref-type="bibr" rid="CR53">53</xref>], highlighting the role of individual susceptibility in ASM-related neuropsychiatric reactions. Alterations in the 5-HT (serotonin) and glutamatergic pathways have also been implicated in ASM-related neuropsychiatric effects, particularly in the manifestation of aggressive behavior, including agitation, anger, hostility, and overt aggression, which may, in some cases, contribute to an increased risk of suicidality [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. In some patients, the rapid suppression of seizures can trigger psychiatric symptoms, a phenomenon known as&#x000a0;"forced normalization" [<xref ref-type="bibr" rid="CR56">56</xref>]. This paradoxical reaction, often associated with psychosis, hypomania, or depression, is thought to involve disrupted balance between excitatory and inhibitory activity in limbic circuits. Forced normalization has been reported with many ASMs and may, at least in part, explain their paradoxical exacerbation of psychiatric symptoms in patients with epilepsy [<xref ref-type="bibr" rid="CR50">50</xref>]. The underlying pathophysiological mechanisms, however, have not been fully characterized.</p><p id="Par50">This study employed real-world data from the FAERS database to investigate AEs related to psychiatric disorders in children associated with ASMs, providing valuable insights and guidance for clinical decision-making. Given the identified associations between ASMs and neuropsychiatric AEs, it is crucial for clinicians to remain vigilant when prescribing these medications, especially in pediatric populations. Healthcare providers should closely monitor children on ASMs for any early signs of mood disturbances, irritability, aggression, or other behavioral symptoms, particularly in those with a history of psychiatric disorders. Regular follow-up and timely intervention are essential to mitigate these adverse effects.</p><p id="Par51">However, several limitations should be acknowledged. Firstly, the FAERS database functions as a spontaneous submission system, rather than imposing strict censorship on all submitted reports, which may lead to reporting bias and information gaps. Despite the standardization of MedDRA terms, variations in symptom descriptions and missing data (such as age or medication doses) may exist. Additionally, reporting bias, such as the overreporting of severe AEs may occur. The absence of denominator data&#x02014;i.e., the total number of individuals exposed to a specific drug&#x02014;prevents the estimation of incidence rates or risk quantification. Furthermore, essential covariates such as polypharmacy, age, and gender were often unavailable or incompletely reported, precluding meaningful adjustment for these potential confounders. As a result, while the detected AE signal can only suggest a statistical association between the drug and the AE, indicating a potential cause, it does not support causal inference. These limitations highlight the importance of interpreting findings alongside complementary clinical, epidemiological, and pharmacological evidence. Second, the use of strict statistical thresholds in signal detection may lead to false-negative results, particularly for rare or underreported events. Such vulnerability is inherent to spontaneous reporting systems and warrants further exploration through sensitivity analyses or complementary approaches such as Natural Language Processing (NLP) of narrative fields. Third, the FAERS report primarily originates from the United States and Europe. The findings may not be generalizable due to ethnic and regional variability in drug response. To improve robustness, future studies should incorporate multiple pharmacovigilance systems (e.g., EudraVigilance, WHO VigiBase) and validate signals using structured clinical data such as electronic health records. Fourth, this study focused on the utilization of a single ASM for signal detection and screening, without considering the potential impact of drug interactions on ADRs. Fifth, while disproportionality analysis remains a powerful tool for detecting ADR signals [<xref ref-type="bibr" rid="CR57">57</xref>]&#x02014;particularly rare or unexpected events&#x02014;it should be noted that it does not constitute a definitive measure of causality or risk. Currently, there is no universally accepted gold standard for ADR signal detection. These methods primarily serve as indicators of potential safety concerns, and their interpretation must be supported by clinical data, case-level assessment, and complementary research approaches [<xref ref-type="bibr" rid="CR58">58</xref>]. Future studies should focus on establishing standardized methodologies for signal detection to ensure consistency and accuracy across pharmacovigilance research. It is worth mentioning that AEs during antiepileptic therapy may reflect genetic susceptibility. Pathogenic variants in neurodevelopmental genes can simultaneously predispose to epilepsy and comorbid neuropsychiatric traits, such as intellectual disability or autism spectrum features, through shared biological pathways [<xref ref-type="bibr" rid="CR59">59</xref>]. This highlights the need for integrating genetic profiling into pharmacovigilance studies of drug-related neuropsychiatric manifestations. Future research should focus on identifying rare genetic variants and susceptibility loci to elucidate molecular mechanisms underlying these adverse drug responses.</p></sec><sec id="Sec7"><title>Conclusions</title><p id="Par52">In this study, the real-world safety characteristics of ASMs were assessed in terms of pharmacovigilance signals by conducting signal detection analysis using the FAERS database. Our focus was on AEs related to psychiatric disorders caused by ASMs in pediatric patients. Although these findings were limited to statistical correlations, they provided valuable information for clinical medication practices aimed at enhancing rationalization and safety measures. Close monitoring is recommended for children receiving ASMs, and if any significant ADRs occur, healthcare providers should be involved to consider dose adjustments or discontinuation of treatment.</p></sec><sec id="Sec8" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="42494_2025_223_MOESM1_ESM.xlsx"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ADHD</term><def><p id="Par5">Attention deficit hyperactivity disorder</p></def></def-item><def-item><term>ADRs</term><def><p id="Par6">Adverse drug reactions</p></def></def-item><def-item><term>AEs</term><def><p id="Par7">Adverse events</p></def></def-item><def-item><term>ASCII</term><def><p id="Par8">American Standard Code for Information Interchange</p></def></def-item><def-item><term>ASD</term><def><p id="Par9">Autism spectrum disorder</p></def></def-item><def-item><term>ASMs</term><def><p id="Par10">Antiseizure medications</p></def></def-item><def-item><term>BCPNN</term><def><p id="Par11">Bayesian confidence propagation neural network</p></def></def-item><def-item><term>DALYs</term><def><p id="Par12">Disability-adjusted life years</p></def></def-item><def-item><term>DS</term><def><p id="Par13">Dravet syndrome</p></def></def-item><def-item><term>DSM-5</term><def><p id="Par14">Diagnostic and Statistical Manual of Mental Disorders-5th Edition</p></def></def-item><def-item><term>FAERS</term><def><p id="Par15">FDA Adverse Event Reporting System</p></def></def-item><def-item><term>ICD-10</term><def><p id="Par16">International Classification of Diseases-10th Edition</p></def></def-item><def-item><term>ILAE</term><def><p id="Par17">International League Against Epilepsy</p></def></def-item><def-item><term>LGS</term><def><p id="Par18">Lennox-Gastaut syndrome</p></def></def-item><def-item><term>MedDRA</term><def><p id="Par19">Medical Dictionary for Regulatory Activities</p></def></def-item><def-item><term>MGPS</term><def><p id="Par20">Multi-item gamma Poisson shrinker</p></def></def-item><def-item><term>NLP</term><def><p id="Par21">Natural language processing</p></def></def-item><def-item><term>PRR</term><def><p id="Par22">Proportional reporting ratio</p></def></def-item><def-item><term>PT</term><def><p id="Par23">Preferred term</p></def></def-item><def-item><term>ROR</term><def><p id="Par24">Reporting odds ratios</p></def></def-item><def-item><term>SOC</term><def><p id="Par25">System organ classification</p></def></def-item></def-list></glossary><fn-group><fn><p>Jianxiong Gui and Lingman Wang contributed equally to this work and share the first authorship.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was performed using the FAERS source that was provided by the FDA. The information, results, or interpretation of the current study do not represent any opinion of the FDA.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>Jianxiong Gui: Conceptualization, Methodology, Software, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing; Lingman Wang: Conceptualization, Methodology, Software, Writing &#x02013; review &#x00026; editing; Linxue Meng: Software, Writing &#x02013; review &#x00026; editing; Xiaofang Zhang: Methodology, Writing &#x02013; review &#x00026; editing; Jiannan Ma: Supervision, Project administration; Li Jiang: Conceptualization, Supervision, Project administration.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by China Postdoctoral Science Foundation (grant number: 2024M760146).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The public can obtain all reported AEs by accessing the official FDA website (<ext-link ext-link-type="uri" xlink:href="https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html">https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html</ext-link>). The dataset generated during and analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par53">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par54">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par55">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RS</given-names></name><name><surname>Acevedo</surname><given-names>C</given-names></name><name><surname>Arzimanoglou</surname><given-names>A</given-names></name><name><surname>Bogacz</surname><given-names>A</given-names></name><name><surname>Cross</surname><given-names>JH</given-names></name><name><surname>Elger</surname><given-names>CE</given-names></name><etal/></person-group><article-title>ILAE official report: a practical clinical definition of epilepsy</article-title><source>Epilepsia</source><year>2014</year><volume>55</volume><issue>4</issue><fpage>475</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1111/epi.12550</pub-id><pub-id pub-id-type="pmid">24730690</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475&#x02013;82.<pub-id pub-id-type="pmid">24730690</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Thijs</surname><given-names>RD</given-names></name><name><surname>Surges</surname><given-names>R</given-names></name><name><surname>O'Brien</surname><given-names>TJ</given-names></name><name><surname>Sander</surname><given-names>JW</given-names></name></person-group><article-title>Epilepsy in adults</article-title><source>Lancet</source><year>2019</year><volume>393</volume><issue>10172</issue><fpage>689</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32596-0</pub-id><pub-id pub-id-type="pmid">30686584</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Thijs RD, Surges R, O&#x02019;Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689&#x02013;701.<pub-id pub-id-type="pmid">30686584</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group><article-title>Defeating epilepsy: A global public health commitment</article-title><source>Epilepsia Open</source><year>2017</year><volume>2</volume><issue>2</issue><fpage>153</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1002/epi4.12010</pub-id><pub-id pub-id-type="pmid">29588944</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Saxena S, Li S. Defeating epilepsy: A global public health commitment. Epilepsia Open. 2017;2(2):153&#x02013;5.<pub-id pub-id-type="pmid">29588944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>G</given-names></name><name><surname>Sander</surname><given-names>JW</given-names></name></person-group><article-title>The global burden of epilepsy report: Implications for low- and middle-income countries</article-title><source>Epilepsy Behav</source><year>2020</year><volume>105</volume><fpage>106949</fpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2020.106949</pub-id><pub-id pub-id-type="pmid">32088583</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Singh G, Sander JW. The global burden of epilepsy report: Implications for low- and middle-income countries. Epilepsy Behav. 2020;105:106949.<pub-id pub-id-type="pmid">32088583</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Symonds</surname><given-names>JD</given-names></name><name><surname>Elliott</surname><given-names>KS</given-names></name><name><surname>Shetty</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>M</given-names></name><name><surname>Brunklaus</surname><given-names>A</given-names></name><name><surname>Cutcutache</surname><given-names>I</given-names></name><etal/></person-group><article-title>Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants</article-title><source>Brain</source><year>2021</year><volume>144</volume><issue>9</issue><fpage>2879</fpage><lpage>2891</lpage><pub-id pub-id-type="doi">10.1093/brain/awab162</pub-id><pub-id pub-id-type="pmid">34687210</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Symonds JD, Elliott KS, Shetty J, Armstrong M, Brunklaus A, Cutcutache I, et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain. 2021;144(9):2879&#x02013;91.<pub-id pub-id-type="pmid">34687210</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>WA</given-names></name><name><surname>Annegers</surname><given-names>JF</given-names></name><name><surname>Kurland</surname><given-names>LT</given-names></name></person-group><article-title>Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935&#x02013;1984</article-title><source>Epilepsia</source><year>1993</year><volume>34</volume><issue>3</issue><fpage>453</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1157.1993.tb02586.x</pub-id><pub-id pub-id-type="pmid">8504780</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935&#x02013;1984. Epilepsia. 1993;34(3):453&#x02013;68.<pub-id pub-id-type="pmid">8504780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Auvin</surname><given-names>S</given-names></name></person-group><article-title>Paediatric epilepsy and cognition</article-title><source>Dev Med Child Neurol</source><year>2022</year><volume>64</volume><issue>12</issue><fpage>1444</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1111/dmcn.15337</pub-id><pub-id pub-id-type="pmid">35801543</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Auvin S. Paediatric epilepsy and cognition. Dev Med Child Neurol. 2022;64(12):1444&#x02013;52.<pub-id pub-id-type="pmid">35801543</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Kanner</surname><given-names>AM</given-names></name><name><surname>Bicchi</surname><given-names>MM</given-names></name></person-group><article-title>Antiseizure Medications for Adults With Epilepsy: A Review</article-title><source>JAMA</source><year>2022</year><volume>327</volume><issue>13</issue><fpage>1269</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.3880</pub-id><pub-id pub-id-type="pmid">35380580</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Kanner AM, Bicchi MM. Antiseizure Medications for Adults With Epilepsy: A Review. JAMA. 2022;327(13):1269&#x02013;81.<pub-id pub-id-type="pmid">35380580</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Patocka</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Nepovimova</surname><given-names>E</given-names></name><name><surname>Kuca</surname><given-names>K</given-names></name></person-group><article-title>Phenytoin - An anti-seizure drug: Overview of its chemistry, pharmacology and toxicology</article-title><source>Food Chem Toxicol</source><year>2020</year><volume>142</volume><fpage>111393</fpage><pub-id pub-id-type="doi">10.1016/j.fct.2020.111393</pub-id><pub-id pub-id-type="pmid">32376339</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Patocka J, Wu Q, Nepovimova E, Kuca K. Phenytoin - An anti-seizure drug: Overview of its chemistry, pharmacology and toxicology. Food Chem Toxicol. 2020;142:111393.<pub-id pub-id-type="pmid">32376339</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Dodson</surname><given-names>WE</given-names></name></person-group><article-title>Carbamazepine efficacy and utilization in children</article-title><source>Epilepsia</source><year>1987</year><volume>28</volume><issue>Suppl 3</issue><fpage>S17</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">3121295</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Dodson WE. Carbamazepine efficacy and utilization in children. Epilepsia. 1987;28(Suppl 3):S17-24.<pub-id pub-id-type="pmid">3121295</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Nanau</surname><given-names>RM</given-names></name><name><surname>Neuman</surname><given-names>MG</given-names></name></person-group><article-title>Adverse drug reactions induced by valproic acid</article-title><source>Clin Biochem</source><year>2013</year><volume>46</volume><issue>15</issue><fpage>1323</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2013.06.012</pub-id><pub-id pub-id-type="pmid">23792104</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323&#x02013;38.<pub-id pub-id-type="pmid">23792104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Culy CR, Goa KL. Lamotrigine. A review of its use in childhood epilepsy. Paediatr Drugs. 2000;2(4):299&#x02013;330.</mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Glauser</surname><given-names>TA</given-names></name></person-group><article-title>Topiramate</article-title><source>Epilepsia</source><year>1999</year><volume>40</volume><issue>Suppl 5</issue><fpage>S71</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10530697</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Glauser TA. Topiramate. Epilepsia. 1999;40(Suppl 5):S71-80.<pub-id pub-id-type="pmid">10530697</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Vigevano</surname><given-names>F</given-names></name></person-group><article-title>Levetiracetam in pediatrics</article-title><source>J Child Neurol</source><year>2005</year><volume>20</volume><issue>2</issue><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1177/08830738050200020101</pub-id><pub-id pub-id-type="pmid">15794171</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Vigevano F. Levetiracetam in pediatrics. J Child Neurol. 2005;20(2):87&#x02013;93.<pub-id pub-id-type="pmid">15794171</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Strzelczyk</surname><given-names>A</given-names></name><name><surname>Z&#x000f6;llner</surname><given-names>JP</given-names></name><name><surname>Willems</surname><given-names>LM</given-names></name><name><surname>Jost</surname><given-names>J</given-names></name><name><surname>Paule</surname><given-names>E</given-names></name><name><surname>Schubert-Bast</surname><given-names>S</given-names></name><etal/></person-group><article-title>Lacosamide in status epilepticus: Systematic review of current evidence</article-title><source>Epilepsia</source><year>2017</year><volume>58</volume><issue>6</issue><fpage>933</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1111/epi.13716</pub-id><pub-id pub-id-type="pmid">28295226</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Strzelczyk A, Z&#x000f6;llner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, et al. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia. 2017;58(6):933&#x02013;50.<pub-id pub-id-type="pmid">28295226</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Herranz</surname><given-names>JL</given-names></name></person-group><article-title>Antiepileptic drugs</article-title><source>Rev Neurol</source><year>2018</year><volume>66</volume><issue>s02</issue><fpage>S21</fpage><lpage>S25</lpage><pub-id pub-id-type="pmid">29876908</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Herranz JL. Antiepileptic drugs. Rev Neurol. 2018;66(s02):S21&#x02013;5.<pub-id pub-id-type="pmid">29876908</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Pironi</surname><given-names>V</given-names></name><name><surname>Ciccone</surname><given-names>O</given-names></name><name><surname>Beghi</surname><given-names>E</given-names></name><name><surname>Paragua-Zuellig</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>AA</given-names></name><name><surname>Giussani</surname><given-names>G</given-names></name><etal/></person-group><article-title>Survey on the worldwide availability and affordability of antiseizure medications: Report of the ILAE Task Force on Access to Treatment</article-title><source>Epilepsia</source><year>2022</year><volume>63</volume><issue>2</issue><fpage>335</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1111/epi.17155</pub-id><pub-id pub-id-type="pmid">34981508</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Pironi V, Ciccone O, Beghi E, Paragua-Zuellig H, Patel AA, Giussani G, et al. Survey on the worldwide availability and affordability of antiseizure medications: Report of the ILAE Task Force on Access to Treatment. Epilepsia. 2022;63(2):335&#x02013;51.<pub-id pub-id-type="pmid">34981508</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamed</surname><given-names>SA</given-names></name></person-group><article-title>Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications</article-title><source>Expert Opin Drug Saf</source><year>2011</year><volume>10</volume><issue>6</issue><fpage>913</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1517/14740338.2011.588597</pub-id><pub-id pub-id-type="pmid">21619486</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Hamed SA. Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications. Expert Opin Drug Saf. 2011;10(6):913&#x02013;34.<pub-id pub-id-type="pmid">21619486</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Verrotti</surname><given-names>A</given-names></name><name><surname>Carrozzino</surname><given-names>D</given-names></name><name><surname>Milioni</surname><given-names>M</given-names></name><name><surname>Minna</surname><given-names>M</given-names></name><name><surname>Fulcheri</surname><given-names>M</given-names></name></person-group><article-title>Epilepsy and its main psychiatric comorbidities in adults and children</article-title><source>J Neurol Sci</source><year>2014</year><volume>343</volume><issue>1&#x02013;2</issue><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2014.05.043</pub-id><pub-id pub-id-type="pmid">24929650</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Verrotti A, Carrozzino D, Milioni M, Minna M, Fulcheri M. Epilepsy and its main psychiatric comorbidities in adults and children. J Neurol Sci. 2014;343(1&#x02013;2):23&#x02013;9.<pub-id pub-id-type="pmid">24929650</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Karadag</surname><given-names>N</given-names></name><name><surname>Shadrin</surname><given-names>AA</given-names></name><name><surname>O'Connell</surname><given-names>KS</given-names></name><name><surname>Hindley</surname><given-names>GFL</given-names></name><name><surname>Rahman</surname><given-names>Z</given-names></name><name><surname>Parker</surname><given-names>N</given-names></name><etal/></person-group><article-title>Identification of novel genomic risk loci shared between common epilepsies and psychiatric disorders</article-title><source>Brain</source><year>2023</year><volume>146</volume><issue>8</issue><fpage>3392</fpage><lpage>3403</lpage><pub-id pub-id-type="doi">10.1093/brain/awad038</pub-id><pub-id pub-id-type="pmid">36757824</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Karadag N, Shadrin AA, O&#x02019;Connell KS, Hindley GFL, Rahman Z, Parker N, et al. Identification of novel genomic risk loci shared between common epilepsies and psychiatric disorders. Brain. 2023;146(8):3392&#x02013;403.<pub-id pub-id-type="pmid">36757824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>C</given-names></name><name><surname>Cavalleri</surname><given-names>GL</given-names></name><name><surname>Delanty</surname><given-names>N</given-names></name></person-group><article-title>Exploring the genetic overlap between psychiatric illness and epilepsy: A review</article-title><source>Epilepsy Behav</source><year>2020</year><volume>102</volume><fpage>106669</fpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2019.106669</pub-id><pub-id pub-id-type="pmid">31785486</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Campbell C, Cavalleri GL, Delanty N. Exploring the genetic overlap between psychiatric illness and epilepsy: A review. Epilepsy Behav. 2020;102:106669.<pub-id pub-id-type="pmid">31785486</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jiao</surname><given-names>XF</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Drug-associated kidney injury in children: a disproportionality analysis of the FDA Adverse Event Reporting System</article-title><source>Eur J Pediatr</source><year>2023</year><volume>182</volume><issue>10</issue><fpage>4655</fpage><lpage>4661</lpage><pub-id pub-id-type="doi">10.1007/s00431-023-05146-2</pub-id><pub-id pub-id-type="pmid">37561197</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Zhang M, Li H, Huang L, Liu Y, Jiao XF, Zeng L, et al. Drug-associated kidney injury in children: a disproportionality analysis of the FDA Adverse Event Reporting System. Eur J Pediatr. 2023;182(10):4655&#x02013;61.<pub-id pub-id-type="pmid">37561197</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Battini</surname><given-names>V</given-names></name><name><surname>Mari</surname><given-names>A</given-names></name><name><surname>Gringeri</surname><given-names>M</given-names></name><name><surname>Casini</surname><given-names>F</given-names></name><name><surname>Bergamaschi</surname><given-names>F</given-names></name><name><surname>Mosini</surname><given-names>G</given-names></name><etal/></person-group><article-title>Antibiotic-induced neutropenia in pediatric patients: new insights from pharmacoepidemiological analyses and a systematic review</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>877932</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.877932</pub-id><pub-id pub-id-type="pmid">35721197</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Battini V, Mari A, Gringeri M, Casini F, Bergamaschi F, Mosini G, et al. Antibiotic-induced neutropenia in pediatric patients: new insights from pharmacoepidemiological analyses and a systematic review. Front Pharmacol. 2022;13:877932.<pub-id pub-id-type="pmid">35721197</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Borrelli</surname><given-names>EP</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Descoteaux</surname><given-names>AM</given-names></name><name><surname>Kogut</surname><given-names>SJ</given-names></name><name><surname>Caffrey</surname><given-names>AR</given-names></name></person-group><article-title>Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System</article-title><source>Epilepsia</source><year>2018</year><volume>59</volume><issue>12</issue><fpage>2318</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1111/epi.14591</pub-id><pub-id pub-id-type="pmid">30395352</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia. 2018;59(12):2318&#x02013;24.<pub-id pub-id-type="pmid">30395352</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name></person-group><article-title>Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database</article-title><source>Seizure</source><year>2024</year><volume>117</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.seizure.2024.03.009</pub-id><pub-id pub-id-type="pmid">38537425</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">He Z, Liu C, Lin L, Feng G, Wu G. Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database. Seizure. 2024;117:253&#x02013;60.<pub-id pub-id-type="pmid">38537425</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Rothman</surname><given-names>KJ</given-names></name><name><surname>Lanes</surname><given-names>S</given-names></name><name><surname>Sacks</surname><given-names>ST</given-names></name></person-group><article-title>The reporting odds ratio and its advantages over the proportional reporting ratio</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2004</year><volume>13</volume><issue>8</issue><fpage>519</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1002/pds.1001</pub-id><pub-id pub-id-type="pmid">15317031</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519&#x02013;23.<pub-id pub-id-type="pmid">15317031</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>SJ</given-names></name><name><surname>Waller</surname><given-names>PC</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name></person-group><article-title>Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2001</year><volume>10</volume><issue>6</issue><fpage>483</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1002/pds.677</pub-id><pub-id pub-id-type="pmid">11828828</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483&#x02013;6.<pub-id pub-id-type="pmid">11828828</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Bate</surname><given-names>A</given-names></name><name><surname>Lindquist</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>IR</given-names></name><name><surname>Olsson</surname><given-names>S</given-names></name><name><surname>Orre</surname><given-names>R</given-names></name><name><surname>Lansner</surname><given-names>A</given-names></name><etal/></person-group><article-title>A Bayesian neural network method for adverse drug reaction signal generation</article-title><source>Eur J Clin Pharmacol</source><year>1998</year><volume>54</volume><issue>4</issue><fpage>315</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1007/s002280050466</pub-id><pub-id pub-id-type="pmid">9696956</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315&#x02013;21.<pub-id pub-id-type="pmid">9696956</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Szarfman</surname><given-names>A</given-names></name><name><surname>Machado</surname><given-names>SG</given-names></name><name><surname>O'Neill</surname><given-names>RT</given-names></name></person-group><article-title>Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database</article-title><source>Drug Saf</source><year>2002</year><volume>25</volume><issue>6</issue><fpage>381</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.2165/00002018-200225060-00001</pub-id><pub-id pub-id-type="pmid">12071774</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Szarfman A, Machado SG, O&#x02019;Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA&#x02019;s spontaneous reports database. Drug Saf. 2002;25(6):381&#x02013;92.<pub-id pub-id-type="pmid">12071774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name></person-group><article-title>Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database</article-title><source>J Affect Disord</source><year>2024</year><volume>346</volume><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2023.11.025</pub-id><pub-id pub-id-type="pmid">37956832</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database. J Affect Disord. 2024;346:223&#x02013;9.<pub-id pub-id-type="pmid">37956832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022</article-title><source>Expert Rev Clin Pharmacol</source><year>2024</year><volume>17</volume><issue>2</issue><fpage>189</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1080/17512433.2024.2306223</pub-id><pub-id pub-id-type="pmid">38269492</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Du Y, Zhu J, Guo Z, Wang Z, Wang Y, Hu M, et al. Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022. Expert Rev Clin Pharmacol. 2024;17(2):189&#x02013;201.<pub-id pub-id-type="pmid">38269492</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Strzelczyk</surname><given-names>A</given-names></name><name><surname>Schubert-Bast</surname><given-names>S</given-names></name></person-group><article-title>Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic Encephalopathies</article-title><source>CNS Drugs</source><year>2022</year><volume>36</volume><issue>10</issue><fpage>1079</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1007/s40263-022-00955-9</pub-id><pub-id pub-id-type="pmid">36194365</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Strzelczyk A, Schubert-Bast S. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic Encephalopathies. CNS Drugs. 2022;36(10):1079&#x02013;111.<pub-id pub-id-type="pmid">36194365</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Gibbon</surname><given-names>FM</given-names></name><name><surname>Maccormac</surname><given-names>E</given-names></name><name><surname>Gringras</surname><given-names>P</given-names></name></person-group><article-title>Sleep and epilepsy: unfortunate bedfellows</article-title><source>Arch Dis Child</source><year>2019</year><volume>104</volume><issue>2</issue><fpage>189</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2017-313421</pub-id><pub-id pub-id-type="pmid">30266875</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Gibbon FM, Maccormac E, Gringras P. Sleep and epilepsy: unfortunate bedfellows. Arch Dis Child. 2019;104(2):189&#x02013;92.<pub-id pub-id-type="pmid">30266875</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Aboukaoud</surname><given-names>M</given-names></name><name><surname>Wilf-Yarkoni</surname><given-names>A</given-names></name><name><surname>Maor</surname><given-names>E</given-names></name></person-group><article-title>Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis</article-title><source>Epilepsia</source><year>2023</year><volume>64</volume><issue>9</issue><fpage>2322</fpage><lpage>2329</lpage><pub-id pub-id-type="doi">10.1111/epi.17696</pub-id><pub-id pub-id-type="pmid">37350356</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Aboukaoud M, Wilf-Yarkoni A, Maor E. Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis. Epilepsia. 2023;64(9):2322&#x02013;9.<pub-id pub-id-type="pmid">37350356</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Hirsch</surname><given-names>LJ</given-names></name><name><surname>Katz</surname><given-names>A</given-names></name><name><surname>Legge</surname><given-names>A</given-names></name><name><surname>Buchsbaum</surname><given-names>R</given-names></name><etal/></person-group><article-title>Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy</article-title><source>Epilepsy Behav</source><year>2017</year><volume>76</volume><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2017.08.039</pub-id><pub-id pub-id-type="pmid">28931473</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24&#x02013;31.<pub-id pub-id-type="pmid">28931473</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Fukatsu</surname><given-names>N</given-names></name><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Oshima</surname><given-names>T</given-names></name><name><surname>Tadokoro</surname><given-names>Y</given-names></name><name><surname>Kanemoto</surname><given-names>K</given-names></name></person-group><article-title>Lamotrigine improves aggression in patients with temporal lobe epilepsy</article-title><source>Epilepsy Behav</source><year>2011</year><volume>21</volume><issue>2</issue><fpage>173</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2011.03.015</pub-id><pub-id pub-id-type="pmid">21514239</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Kato H, Fukatsu N, Noguchi T, Oshima T, Tadokoro Y, Kanemoto K. Lamotrigine improves aggression in patients with temporal lobe epilepsy. Epilepsy Behav. 2011;21(2):173&#x02013;6.<pub-id pub-id-type="pmid">21514239</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Shioda</surname><given-names>K</given-names></name><name><surname>Nisijima</surname><given-names>K</given-names></name></person-group><article-title>Anger with murderous impulse induced by lamotrigine</article-title><source>Gen Hosp Psychiatry</source><year>2014</year><volume>36</volume><issue>4</issue><fpage>451.e1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/j.genhosppsych.2014.03.008</pub-id><pub-id pub-id-type="pmid">24736088</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Saito S, Shioda K, Nisijima K. Anger with murderous impulse induced by lamotrigine. Gen Hosp Psychiatry. 2014;36(4):451.e1-2.<pub-id pub-id-type="pmid">24736088</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Canitano R, Bozzi Y. Autism Spectrum Disorder with Epilepsy: A Research Protocol for a Clinical and Genetic Study. Genes. 2023;15(1).</mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Bootsma</surname><given-names>HP</given-names></name><name><surname>Vos</surname><given-names>AM</given-names></name><name><surname>Hulsman</surname><given-names>J</given-names></name><name><surname>Lambrechts</surname><given-names>D</given-names></name><name><surname>Leenen</surname><given-names>L</given-names></name><name><surname>Majoie</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center</article-title><source>Epilepsy Behav</source><year>2008</year><volume>12</volume><issue>2</issue><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2007.10.004</pub-id><pub-id pub-id-type="pmid">18093878</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Bootsma HP, Vos AM, Hulsman J, Lambrechts D, Leenen L, Majoie M, et al. Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. 2008;12(2):262&#x02013;8.<pub-id pub-id-type="pmid">18093878</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Aldenkamp</surname><given-names>AP</given-names></name><name><surname>Baker</surname><given-names>G</given-names></name></person-group><article-title>A Systematic Review of the Effects of Lamotrigine on Cognitive Function and Quality of Life</article-title><source>Epilepsy Behav</source><year>2001</year><volume>2</volume><issue>2</issue><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1006/ebeh.2001.0168</pub-id><pub-id pub-id-type="pmid">12609190</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Aldenkamp AP, Baker G. A Systematic Review of the Effects of Lamotrigine on Cognitive Function and Quality of Life. Epilepsy Behav. 2001;2(2):85&#x02013;91.<pub-id pub-id-type="pmid">12609190</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Dooley</surname><given-names>JM</given-names></name><name><surname>Camfield</surname><given-names>PR</given-names></name><name><surname>Smith</surname><given-names>E</given-names></name><name><surname>Langevin</surname><given-names>P</given-names></name><name><surname>Ronen</surname><given-names>G</given-names></name></person-group><article-title>Topiramate in intractable childhood onset epilepsy&#x02013;a cautionary note</article-title><source>Can J Neurol Sci</source><year>1999</year><volume>26</volume><issue>4</issue><fpage>271</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1017/S0317167100000366</pub-id><pub-id pub-id-type="pmid">10563211</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Dooley JM, Camfield PR, Smith E, Langevin P, Ronen G. Topiramate in intractable childhood onset epilepsy&#x02013;a cautionary note. Can J Neurol Sci. 1999;26(4):271&#x02013;3.<pub-id pub-id-type="pmid">10563211</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Schjerning</surname><given-names>O</given-names></name><name><surname>Rosenzweig</surname><given-names>M</given-names></name><name><surname>Potteg&#x000e5;rd</surname><given-names>A</given-names></name><name><surname>Damkier</surname><given-names>P</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name></person-group><article-title>Abuse Potential of Pregabalin: A Systematic Review</article-title><source>CNS Drugs</source><year>2016</year><volume>30</volume><issue>1</issue><fpage>9</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/s40263-015-0303-6</pub-id><pub-id pub-id-type="pmid">26767525</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Schjerning O, Rosenzweig M, Potteg&#x000e5;rd A, Damkier P, Nielsen J. Abuse Potential of Pregabalin: A Systematic Review. CNS Drugs. 2016;30(1):9&#x02013;25.<pub-id pub-id-type="pmid">26767525</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Brodie</surname><given-names>MJ</given-names></name><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Wade</surname><given-names>A</given-names></name><name><surname>Quelen</surname><given-names>C</given-names></name><name><surname>Guiraud-Diawara</surname><given-names>A</given-names></name><name><surname>Francois</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study</article-title><source>Epilepsy Res</source><year>2016</year><volume>123</volume><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.eplepsyres.2016.04.003</pub-id><pub-id pub-id-type="pmid">27135706</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Brodie MJ, Chung S, Wade A, Quelen C, Guiraud-Diawara A, Francois C, et al. Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study. Epilepsy Res. 2016;123:68&#x02013;74.<pub-id pub-id-type="pmid">27135706</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Livingston JH, Beaumont D, Arzimanoglou A, Aicardi J. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol. 1989;27 Suppl 1(Suppl 1):109s-12s.</mixed-citation></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Dreier</surname><given-names>JW</given-names></name><name><surname>Pedersen</surname><given-names>CB</given-names></name><name><surname>Gasse</surname><given-names>C</given-names></name><name><surname>Christensen</surname><given-names>J</given-names></name></person-group><article-title>Antiepileptic Drugs and Suicide: Role of Prior Suicidal Behavior and Parental Psychiatric Disorder</article-title><source>Ann Neurol</source><year>2019</year><volume>86</volume><issue>6</issue><fpage>951</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1002/ana.25623</pub-id><pub-id pub-id-type="pmid">31621936</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Dreier JW, Pedersen CB, Gasse C, Christensen J. Antiepileptic Drugs and Suicide: Role of Prior Suicidal Behavior and Parental Psychiatric Disorder. Ann Neurol. 2019;86(6):951&#x02013;61.<pub-id pub-id-type="pmid">31621936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>P</given-names></name><name><surname>Devinsky</surname><given-names>O</given-names></name><name><surname>French</surname><given-names>J</given-names></name><name><surname>Harden</surname><given-names>C</given-names></name><name><surname>Krauss</surname><given-names>GL</given-names></name><name><surname>McCarter</surname><given-names>R</given-names></name><etal/></person-group><article-title>Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis</article-title><source>JAMA Neurol</source><year>2021</year><volume>78</volume><issue>9</issue><fpage>1118</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2021.2480</pub-id><pub-id pub-id-type="pmid">34338718</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Klein P, Devinsky O, French J, Harden C, Krauss GL, McCarter R, et al. Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis. JAMA Neurol. 2021;78(9):1118&#x02013;27.<pub-id pub-id-type="pmid">34338718</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Spina</surname><given-names>E</given-names></name><name><surname>Perugi</surname><given-names>G</given-names></name></person-group><article-title>Antiepileptic drugs: indications other than epilepsy</article-title><source>Epileptic Disord</source><year>2004</year><volume>6</volume><issue>2</issue><fpage>57</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1684/j.1950-6945.2004.tb00053.x</pub-id><pub-id pub-id-type="pmid">15246950</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 2004;6(2):57&#x02013;75.<pub-id pub-id-type="pmid">15246950</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Salpekar</surname><given-names>JA</given-names></name><name><surname>Ertenu</surname><given-names>DD</given-names></name></person-group><article-title>Common ground: we can comprehensively treat pediatric epilepsy and psychiatric comorbidities</article-title><source>Epilepsy currents</source><year>2024</year><volume>24</volume><issue>6</issue><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1177/15357597241250159</pub-id><pub-id pub-id-type="pmid">39544724</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Salpekar JA, Ertenu DD. Common ground: we can comprehensively treat pediatric epilepsy and psychiatric comorbidities. Epilepsy currents. 2024;24(6):381&#x02013;6.<pub-id pub-id-type="pmid">39544724</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f6;scher</surname><given-names>W</given-names></name><name><surname>Potschka</surname><given-names>H</given-names></name><name><surname>Sisodiya</surname><given-names>SM</given-names></name><name><surname>Vezzani</surname><given-names>A</given-names></name></person-group><article-title>Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options</article-title><source>Pharmacol Rev</source><year>2020</year><volume>72</volume><issue>3</issue><fpage>606</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1124/pr.120.019539</pub-id><pub-id pub-id-type="pmid">32540959</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">L&#x000f6;scher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72(3):606&#x02013;38.<pub-id pub-id-type="pmid">32540959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Perucca</surname><given-names>P</given-names></name><name><surname>Mula</surname><given-names>M</given-names></name></person-group><article-title>Antiepileptic drug effects on mood and behavior: molecular targets</article-title><source>Epilepsy Behav</source><year>2013</year><volume>26</volume><issue>3</issue><fpage>440</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2012.09.018</pub-id><pub-id pub-id-type="pmid">23092694</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav. 2013;26(3):440&#x02013;9.<pub-id pub-id-type="pmid">23092694</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Sanacora</surname><given-names>G</given-names></name><name><surname>Saricicek</surname><given-names>A</given-names></name></person-group><article-title>GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action</article-title><source>CNS Neurol Disord: Drug Targets</source><year>2007</year><volume>6</volume><issue>2</issue><fpage>127</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.2174/187152707780363294</pub-id><pub-id pub-id-type="pmid">17430150</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Sanacora G, Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord: Drug Targets. 2007;6(2):127&#x02013;40.<pub-id pub-id-type="pmid">17430150</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Coccaro</surname><given-names>EF</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Vezina</surname><given-names>P</given-names></name></person-group><article-title>Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects</article-title><source>J Psychiatr Res</source><year>2013</year><volume>47</volume><issue>9</issue><fpage>1247</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2013.05.001</pub-id><pub-id pub-id-type="pmid">23791397</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Coccaro EF, Lee R, Vezina P. Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects. J Psychiatr Res. 2013;47(9):1247&#x02013;53.<pub-id pub-id-type="pmid">23791397</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Loring</surname><given-names>DW</given-names></name><name><surname>Marino</surname><given-names>S</given-names></name><name><surname>Meador</surname><given-names>KJ</given-names></name></person-group><article-title>Neuropsychological and behavioral effects of antiepilepsy drugs</article-title><source>Neuropsychol Rev</source><year>2007</year><volume>17</volume><issue>4</issue><fpage>413</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1007/s11065-007-9043-9</pub-id><pub-id pub-id-type="pmid">17943448</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev. 2007;17(4):413&#x02013;25.<pub-id pub-id-type="pmid">17943448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>CC</given-names></name><name><surname>Ljung</surname><given-names>H</given-names></name><name><surname>Brodtkorb</surname><given-names>E</given-names></name><name><surname>Reimers</surname><given-names>A</given-names></name></person-group><article-title>Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel</article-title><source>Behav Neurol</source><year>2018</year><volume>2018</volume><fpage>2064027</fpage><pub-id pub-id-type="doi">10.1155/2018/2064027</pub-id><pub-id pub-id-type="pmid">30581496</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel. Behav Neurol. 2018;2018:2064027.<pub-id pub-id-type="pmid">30581496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Mula</surname><given-names>M</given-names></name><name><surname>Sander</surname><given-names>JW</given-names></name></person-group><article-title>Suicide and epilepsy: do antiepileptic drugs increase the risk?</article-title><source>Expert Opin Drug Saf</source><year>2015</year><volume>14</volume><issue>4</issue><fpage>553</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1517/14740338.2015.1010506</pub-id><pub-id pub-id-type="pmid">25645424</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Mula M, Sander JW. Suicide and epilepsy: do antiepileptic drugs increase the risk? Expert Opin Drug Saf. 2015;14(4):553&#x02013;8.<pub-id pub-id-type="pmid">25645424</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnamoorthy</surname><given-names>ES</given-names></name><name><surname>Trimble</surname><given-names>MR</given-names></name><name><surname>Sander</surname><given-names>JW</given-names></name><name><surname>Kanner</surname><given-names>AM</given-names></name></person-group><article-title>Forced normalization at the interface between epilepsy and psychiatry</article-title><source>Epilepsy Behav</source><year>2002</year><volume>3</volume><issue>4</issue><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/S1525-5050(02)00052-5</pub-id><pub-id pub-id-type="pmid">12609326</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Krishnamoorthy ES, Trimble MR, Sander JW, Kanner AM. Forced normalization at the interface between epilepsy and psychiatry. Epilepsy Behav. 2002;3(4):303&#x02013;8.<pub-id pub-id-type="pmid">12609326</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Bate</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>SJ</given-names></name></person-group><article-title>Quantitative signal detection using spontaneous ADR reporting</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2009</year><volume>18</volume><issue>6</issue><fpage>427</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1002/pds.1742</pub-id><pub-id pub-id-type="pmid">19358225</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427&#x02013;36.<pub-id pub-id-type="pmid">19358225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Raschi</surname><given-names>E</given-names></name><name><surname>Gatti</surname><given-names>M</given-names></name><name><surname>Gelsomino</surname><given-names>F</given-names></name><name><surname>Ardizzoni</surname><given-names>A</given-names></name><name><surname>Poluzzi</surname><given-names>E</given-names></name><name><surname>De Ponti</surname><given-names>F</given-names></name></person-group><article-title>Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance</article-title><source>Target Oncol</source><year>2020</year><volume>15</volume><issue>4</issue><fpage>449</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1007/s11523-020-00738-6</pub-id><pub-id pub-id-type="pmid">32725437</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Target Oncol. 2020;15(4):449&#x02013;66.<pub-id pub-id-type="pmid">32725437</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>AB</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name><name><surname>Bernier</surname><given-names>RA</given-names></name></person-group><article-title>Reflections on the genetics-first approach to advancements in molecular genetic and neurobiological research on neurodevelopmental disorders</article-title><source>J Neurodev Disord</source><year>2021</year><volume>13</volume><issue>1</issue><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/s11689-021-09371-4</pub-id><pub-id pub-id-type="pmid">34148555</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Arnett AB, Wang T, Eichler EE, Bernier RA. Reflections on the genetics-first approach to advancements in molecular genetic and neurobiological research on neurodevelopmental disorders. J Neurodev Disord. 2021;13(1):24.<pub-id pub-id-type="pmid">34148555</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>